<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156646</url>
  </required_header>
  <id_info>
    <org_study_id>WP41047</org_study_id>
    <nct_id>NCT04156646</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers</brief_title>
  <official_title>A Single-Center, Part-Randomized, Open-Label, Single-Dose, Three-Period, Crossover Study to Investigate the Effect of Esomeprazole and The Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effect of food and the effect of esomeprazole on the&#xD;
      pharmacokinetics (PK) of a single dose of balovaptan in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Actual">January 6, 2020</completion_date>
  <primary_completion_date type="Actual">December 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Maximum plasma concentration of Balovaptan is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve (time 0 to infinity) of Balovaptan is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve of Balovaptan from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of Balovaptan is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Cmax in Plasma (Tmax) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Time to maximum plasma concentration of Balovaptan is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Last Quantifiable Concentration (Clast) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time To the Last Quantifiable Concentration (Tlast) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Between Dosing and Time of First Balovaptan Plasma Concentration (Tlag)</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Time between dosing and time of first balovaptan plasma concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (Cl/F) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Apparent clearance is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Apparent volume of distribution is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Phase Half-Life (T1/2) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Rate Constant (Î»z) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Amount of Balovaptan in a given volume of plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Maximum plasma concentration of M2 Metabolite is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Maximum plasma concentration of M3 Metabolite is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Maximum plasma concentration of Esomeprazole is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve (time 0 to infinity) of M2 Metabolite is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve (time 0 to infinity) of M3 Metabolite is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve (time 0 to infinity) of Esomeprazole is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve of M2 Metabolite from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve of M3 Metabolite from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of M2 Metabolite is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of M3 Metabolite is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of Esomeprazole is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax in Plasma (Tmax) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Time to maximum plasma concentration of M2 Metabolite is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax in Plasma (Tmax) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Time to maximum plasma concentration of M3 Metabolite is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax in Plasma (Tmax) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Time to maximum plasma concentration of Esomeprazole is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Quantifiable Concentration (Clast) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Quantifiable Concentration (Clast) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Quantifiable Concentration (Clast) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To the Last Quantifiable Concentration (Tlast) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To the Last Quantifiable Concentration (Tlast) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To the Last Quantifiable Concentration (Tlast) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Phase Half-Life (T1/2) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Phase Half-Life (T1/2) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Phase Half-Life (T1/2) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patricipants With Adverse Events (AEs)</measure>
    <time_frame>Randomization to end of study (up to approximately 7 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Rate Constant (Î»z) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Rate Constant (Î»z) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Rate Constant (Î»z) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of M2 Analyte</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Amount of M2 Analyte in a given volume of plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of M3 Analyte</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
    <description>Amount of M3 Analyte in a given volume of plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
    <description>Amount of Esomeprazole in a given volume of plasma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balovaptan</intervention_name>
    <description>Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No evidence of any active or chronic disease&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kg/m2 inclusive, at screening&#xD;
&#xD;
          -  For women of childbearing potential: if engaging in heterosexual activity, agreement&#xD;
             to use at least two adequate forms of contraception during the entire study and for 90&#xD;
             days following the last dose of study drug&#xD;
&#xD;
          -  For men: agreement to use contraceptive measures, and agreement to refrain from&#xD;
             donating sperm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation (positive serum pregnancy test at screening or at admission)&#xD;
&#xD;
          -  Any condition or disease detected during the medical interview/physical examination&#xD;
             that would render the subject unsuitable for the study, place the subject at undue&#xD;
             risk or interfere with the ability of the subject to complete the study in the opinion&#xD;
             of the Investigator&#xD;
&#xD;
          -  In the opinion of the Investigator, any major illness within 4 weeks prior to the&#xD;
             screening examination or any febrile illness within 1 week prior to screening.&#xD;
&#xD;
          -  History of any clinically significant, as determined by the investigator,&#xD;
             gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric,&#xD;
             cardiovascular, endocrinological, hematological, lymphatic, musculoskeletal,&#xD;
             genitourinary, immunological, dermatological, or connective tissue or allergic&#xD;
             disease, metabolic disorder, or cancer&#xD;
&#xD;
          -  Signs and symptoms potentially indicative of peripheral neuropathy&#xD;
&#xD;
          -  History or evidence of any medical condition potentially altering the absorption,&#xD;
             distribution, metabolism, or elimination of drugs&#xD;
&#xD;
          -  A history of clinically significant in the opinion of the Investigator&#xD;
             hypersensitivity&#xD;
&#xD;
          -  History or presence of clinically significant ECG abnormalities before study drug&#xD;
             administration&#xD;
&#xD;
          -  Clinically significant abnormalities in laboratory test results&#xD;
&#xD;
          -  History of coagulopathies, bleeding disorders, or blood dyscrasias&#xD;
&#xD;
          -  Current suicidal risk, in the opinion of the Investigator&#xD;
&#xD;
          -  Unexplained syncope during the 6 months prior to screening or with presyncopal and/or&#xD;
             syncopal symptoms during orthostatic challenge testing&#xD;
&#xD;
          -  Current smoker or user of tobacco or nicotine-containing products or subjects who have&#xD;
             smoked or used tobacco or nicotine-containing products within 3 months prior to first&#xD;
             study drug administration&#xD;
&#xD;
          -  Suspicion of or presence of a clinically relevant history of or current alcohol and/or&#xD;
             other substance abuse or addiction.&#xD;
&#xD;
          -  Alcohol consumption of &gt;14 units per week for males and females&#xD;
&#xD;
          -  Positive urine alcohol test or urine drug screen at screening or Day -1 of any&#xD;
             treatment period&#xD;
&#xD;
          -  Hormone replacement therapy if postmenopausal status cannot be ascertained from&#xD;
             medical history or FSH levels&#xD;
&#xD;
          -  Clinically relevant deviation from normal in the physical examination including vital&#xD;
             signs, as determined by the investigator&#xD;
&#xD;
          -  Positive result for HIV 1, HIV 2, hepatitis C virus antibody, or hepatitis B core&#xD;
             (HBc) antibody.&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 4 weeks or 5 times the&#xD;
             elimination half-life, whichever is longer, prior to first dosing, or within 5 months&#xD;
             prior to first administration of study drug in case of a study with a biological, as&#xD;
             calculated from the day of Follow-up visit from the previous study&#xD;
&#xD;
          -  Donation of blood or plasma or significant blood loss within 3 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Dietary restrictions that would prohibit the consumption of standardized meals or the&#xD;
             highfat, high-calorie meal planned for this study&#xD;
&#xD;
          -  Use of any prohibited medications or food before study start or subjects who do not&#xD;
             agree to refrain from consuming prohibited medications or food during the study&#xD;
&#xD;
          -  Conditions requiring concomitant medication during the study (including for dental&#xD;
             conditions).&#xD;
&#xD;
          -  Any prescribed systemic or topical medication within 4 weeks (or within 5 times the&#xD;
             elimination half-life of the medication, whichever is longer) of the first&#xD;
             administration of study drug&#xD;
&#xD;
          -  Used any nonprescribed systemic or topical medication or herbal remedies within 7 days&#xD;
             before the first study drug administration&#xD;
&#xD;
          -  Received any medications known to chronically alter drug absorption or elimination&#xD;
             processes within 4 weeks before the first administration of study drug&#xD;
&#xD;
          -  Use of any drugs or substances, including herbal treatments such as St John's wort,&#xD;
             that are known to be substrates, inducers, or inhibitors of CYP3A4 within 4 weeks&#xD;
             before the first administration of study drug&#xD;
&#xD;
          -  Use of any drugs or substances, including herbal treatments, such as fluoxetine,&#xD;
             fluvoxamine, aspirin, norethisterone, rifampicin, etc that are known to be substrates,&#xD;
             inducers, or inhibitors of CYP2C19 within 4 weeks before the first administration of&#xD;
             study drug&#xD;
&#xD;
          -  Subjects under judicial supervision, guardianship, or curatorship&#xD;
&#xD;
          -  Poor venous access for blood sampling&#xD;
&#xD;
          -  Participants who are intolerant to sucrose&#xD;
&#xD;
          -  Previous exposure to balovaptan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International Clinical Pharmacology Center (EDS US Clinic)</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <results_first_submitted>December 1, 2020</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT04156646/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Screening was conducted between Day -28 and Day -2.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence ABC</title>
          <description>Participants were randomized to ABC sequence on Day 1 of Period 1 with the treatments being as follows:&#xD;
Treatment A: 20 mg balovaptan administered as a single oral dose following consumption of high-fat, high-calorie meal&#xD;
Treatment B: 20 mg balovaptan administered as a single oral dose after a â¥10-hour fast&#xD;
Treatment C: 40 mg esomeprazole administered once daily (QD) for 6 days and with a single dose of balovaptan 20 mg in the fasted state 1 hour after the fifth esomeprazole dose</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence BAC</title>
          <description>Participants were randomized to BAC sequence on Day 1 of Period 1 with the treatments being as follows:&#xD;
Treatment B: 20 mg balovaptan administered as a single oral dose after a â¥10-hour fast&#xD;
Treatment A: 20 mg balovaptan administered as a single oral dose following consumption of high-fat, high-calorie meal&#xD;
Treatment C: 40 mg esomeprazole administered once daily (QD) for 6 days and with a single dose of balovaptan 20 mg in the fasted state 1 hour after the fifth esomeprazole dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out Period (12- to 21-days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out Period (12- to 21-days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3 (6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Sequence ABC</title>
          <description>Participants were randomized to ABC sequence on Day 1 of Period 1 with the treatments being as follows:&#xD;
Treatment A: 20 mg balovaptan administered as a single oral dose following consumption of high-fat, high-calorie meal&#xD;
Treatment B: 20 mg balovaptan administered as a single oral dose after a â¥10-hour fast&#xD;
Treatment C: 40 mg esomeprazole administered once daily (QD) for 6 days and with a single dose of balovaptan 20 mg in the fasted state 1 hour after the fifth esomeprazole dose</description>
        </group>
        <group group_id="B2">
          <title>Treatment Sequence BAC</title>
          <description>Participants were randomized to BAC sequence on Day 1 of Period 1 with the treatments being as follows:&#xD;
Treatment B: 20 mg balovaptan administered as a single oral dose after a â¥10-hour fast&#xD;
Treatment A: 20 mg balovaptan administered as a single oral dose following consumption of high-fat, high-calorie meal&#xD;
Treatment C: 40 mg esomeprazole administered once daily (QD) for 6 days and with a single dose of balovaptan 20 mg in the fasted state 1 hour after the fifth esomeprazole dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="11.96"/>
                    <measurement group_id="B2" value="47.1" spread="13.26"/>
                    <measurement group_id="B3" value="43.2" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Balovaptan</title>
        <description>Maximum plasma concentration of Balovaptan is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Balovaptan</title>
          <description>Maximum plasma concentration of Balovaptan is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.83" spread="42.6"/>
                    <measurement group_id="O2" value="97.44" spread="44.6"/>
                    <measurement group_id="O3" value="79.67" spread="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Balovaptan</title>
        <description>Area under the plasma concentration-time curve (time 0 to infinity) of Balovaptan is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>For one participant with Balovaptan 20 mg Fasted+ Esomeprazole 40 mg Fasted, AUC(0-inf)%extrap was &gt; 20%, so AUC(0-inf) and T1/2 were not included in summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Balovaptan</title>
          <description>Area under the plasma concentration-time curve (time 0 to infinity) of Balovaptan is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
          <population>For one participant with Balovaptan 20 mg Fasted+ Esomeprazole 40 mg Fasted, AUC(0-inf)%extrap was &gt; 20%, so AUC(0-inf) and T1/2 were not included in summary statistics.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1736.7" spread="51.3"/>
                    <measurement group_id="O2" value="1705.7" spread="55.9"/>
                    <measurement group_id="O3" value="1820.0" spread="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of Balovaptan</title>
        <description>Area under the plasma concentration-time curve of Balovaptan from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of Balovaptan</title>
          <description>Area under the plasma concentration-time curve of Balovaptan from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="935.2" spread="31.7"/>
                    <measurement group_id="O2" value="945.2" spread="30.8"/>
                    <measurement group_id="O3" value="965.0" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Balovaptan</title>
        <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of Balovaptan is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Balovaptan</title>
          <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of Balovaptan is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1671.0" spread="50.2"/>
                    <measurement group_id="O2" value="1636.1" spread="53.3"/>
                    <measurement group_id="O3" value="1650.9" spread="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Cmax in Plasma (Tmax) of Balovaptan</title>
        <description>Time to maximum plasma concentration of Balovaptan is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax in Plasma (Tmax) of Balovaptan</title>
          <description>Time to maximum plasma concentration of Balovaptan is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Last Quantifiable Concentration (Clast) of Balovaptan</title>
        <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Last Quantifiable Concentration (Clast) of Balovaptan</title>
          <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.693" spread="45.2"/>
                    <measurement group_id="O2" value="1.745" spread="57.3"/>
                    <measurement group_id="O3" value="2.253" spread="142.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time To the Last Quantifiable Concentration (Tlast) of Balovaptan</title>
        <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time To the Last Quantifiable Concentration (Tlast) of Balovaptan</title>
          <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.86" spread="33.4"/>
                    <measurement group_id="O2" value="113.79" spread="35.0"/>
                    <measurement group_id="O3" value="103.58" spread="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Between Dosing and Time of First Balovaptan Plasma Concentration (Tlag)</title>
        <description>Time between dosing and time of first balovaptan plasma concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time Between Dosing and Time of First Balovaptan Plasma Concentration (Tlag)</title>
          <description>Time between dosing and time of first balovaptan plasma concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2500" lower_limit="0.0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.2500" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.2500" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance (Cl/F) of Balovaptan</title>
        <description>Apparent clearance is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (Cl/F) of Balovaptan</title>
          <description>Apparent clearance is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.51" spread="35.7"/>
                    <measurement group_id="O2" value="11.73" spread="36.3"/>
                    <measurement group_id="O3" value="11.26" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vd/F) of Balovaptan</title>
        <description>Apparent volume of distribution is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F) of Balovaptan</title>
          <description>Apparent volume of distribution is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.7" spread="28.7"/>
                    <measurement group_id="O2" value="422.5" spread="33.4"/>
                    <measurement group_id="O3" value="429.4" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Phase Half-Life (T1/2) of Balovaptan</title>
        <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>For one participant with Balovaptan 20 mg Fasted+ Esomeprazole 40 mg Fasted, AUC(0-inf)%extrap was &gt; 20%, so AUC(0-inf) and T1/2 were not included in summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Phase Half-Life (T1/2) of Balovaptan</title>
          <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <population>For one participant with Balovaptan 20 mg Fasted+ Esomeprazole 40 mg Fasted, AUC(0-inf)%extrap was &gt; 20%, so AUC(0-inf) and T1/2 were not included in summary statistics.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.44" spread="40.0"/>
                    <measurement group_id="O2" value="24.98" spread="47.0"/>
                    <measurement group_id="O3" value="27.26" spread="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of M2 Metabolite</title>
        <description>Maximum plasma concentration of M2 Metabolite is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of M2 Metabolite</title>
          <description>Maximum plasma concentration of M2 Metabolite is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27" spread="27.0"/>
                    <measurement group_id="O2" value="11.44" spread="30.8"/>
                    <measurement group_id="O3" value="11.68" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of M3 Metabolite</title>
        <description>Maximum plasma concentration of M3 Metabolite is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of M3 Metabolite</title>
          <description>Maximum plasma concentration of M3 Metabolite is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.96" spread="37.0"/>
                    <measurement group_id="O2" value="16.91" spread="40.8"/>
                    <measurement group_id="O3" value="16.85" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Esomeprazole</title>
        <description>Maximum plasma concentration of Esomeprazole is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Esomeprazole</title>
          <description>Maximum plasma concentration of Esomeprazole is estimated using non-compartmental methods. Observed peak analyte concentration obtained directly from the experimental data without interpolation, expressed in concentration units</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1255.2" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M2 Metabolite</title>
        <description>Area under the plasma concentration-time curve (time 0 to infinity) of M2 Metabolite is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>For one participant (Balovaptan 20 mg Fasted, Balovaptan 20 mg Fasted + Esomeprazole) AUC(0-inf)%extrap was &gt; 20%, so AUC(0-inf) was not included in summary statistics. For one participant in Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fastedthere was no terminal phase, so AUC(0-inf) could not be calculated. One participant was discontinued in Period 3 with Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted after withdrawal of consent.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M2 Metabolite</title>
          <description>Area under the plasma concentration-time curve (time 0 to infinity) of M2 Metabolite is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
          <population>For one participant (Balovaptan 20 mg Fasted, Balovaptan 20 mg Fasted + Esomeprazole) AUC(0-inf)%extrap was &gt; 20%, so AUC(0-inf) was not included in summary statistics. For one participant in Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fastedthere was no terminal phase, so AUC(0-inf) could not be calculated. One participant was discontinued in Period 3 with Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted after withdrawal of consent.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="987.3" spread="27.5"/>
                    <measurement group_id="O2" value="998.5" spread="22.7"/>
                    <measurement group_id="O3" value="1087.7" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M3 Metabolite</title>
        <description>Area under the plasma concentration-time curve (time 0 to infinity) of M3 Metabolite is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>Balovaptan 20 mg Fed: 3 participants were exluded from the analysis due to AUC(0-inf)%extrap &gt; 20% Balovaptan 20 mg Fasted: 3 participants were exluded from the analysis due to AUC(0-inf)%extrap &gt; 20% Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted: 4 participants were exluded from the analysis due to AUC(0-inf)%extrap &gt; 20%. One additional participant was discontinued in Period 3 with Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted after withdrawal of consent.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M3 Metabolite</title>
          <description>Area under the plasma concentration-time curve (time 0 to infinity) of M3 Metabolite is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
          <population>Balovaptan 20 mg Fed: 3 participants were exluded from the analysis due to AUC(0-inf)%extrap &gt; 20% Balovaptan 20 mg Fasted: 3 participants were exluded from the analysis due to AUC(0-inf)%extrap &gt; 20% Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted: 4 participants were exluded from the analysis due to AUC(0-inf)%extrap &gt; 20%. One additional participant was discontinued in Period 3 with Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted after withdrawal of consent.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1552.9" spread="26.2"/>
                    <measurement group_id="O2" value="1590.0" spread="26.9"/>
                    <measurement group_id="O3" value="1723.2" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Esomeprazole</title>
        <description>Area under the plasma concentration-time curve (time 0 to infinity) of Esomeprazole is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <population>3 participants were excluded from the analysis due to missing data. For one of those the value was excluded due to AUC(0-inf)%extrap &gt; 20%.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Esomeprazole</title>
          <description>Area under the plasma concentration-time curve (time 0 to infinity) of Esomeprazole is estimated using non-compartmental methods from the concentration-time profiles. Percent extrapolation less than or equal to 20% is required to obtain a reliable AUC0-inf.</description>
          <population>3 participants were excluded from the analysis due to missing data. For one of those the value was excluded due to AUC(0-inf)%extrap &gt; 20%.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4570.1" spread="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M2 Metabolite</title>
        <description>Area under the plasma concentration-time curve of M2 Metabolite from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M2 Metabolite</title>
          <description>Area under the plasma concentration-time curve of M2 Metabolite from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.6" spread="38.3"/>
                    <measurement group_id="O2" value="180.1" spread="39.5"/>
                    <measurement group_id="O3" value="182.2" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M3 Metabolite</title>
        <description>Area under the plasma concentration-time curve of M3 Metabolite from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M3 Metabolite</title>
          <description>Area under the plasma concentration-time curve of M3 Metabolite from time 0 to 24 hours post-dose is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.8" spread="40.9"/>
                    <measurement group_id="O2" value="325.1" spread="42.0"/>
                    <measurement group_id="O3" value="325.5" spread="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M2 Metabolite</title>
        <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of M2 Metabolite is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M2 Metabolite</title>
          <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of M2 Metabolite is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="897.6" spread="27.2"/>
                    <measurement group_id="O2" value="869.4" spread="26.9"/>
                    <measurement group_id="O3" value="873.9" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M3 Metabolite</title>
        <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of M3 Metabolite is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M3 Metabolite</title>
          <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of M3 Metabolite is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1389.6" spread="23.9"/>
                    <measurement group_id="O2" value="1462.8" spread="29.3"/>
                    <measurement group_id="O3" value="1384.3" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Esomeprazole</title>
        <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of Esomeprazole is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Esomeprazole</title>
          <description>Area under the concentration-time curve (time 0 to time of last quantifiable concentration) of Esomeprazole is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4014.9" spread="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Cmax in Plasma (Tmax) of M2 Metabolite</title>
        <description>Time to maximum plasma concentration of M2 Metabolite is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax in Plasma (Tmax) of M2 Metabolite</title>
          <description>Time to maximum plasma concentration of M2 Metabolite is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.00" lower_limit="16.00" upper_limit="48.00"/>
                    <measurement group_id="O2" value="24.03" lower_limit="16.00" upper_limit="48.00"/>
                    <measurement group_id="O3" value="36.00" lower_limit="12.00" upper_limit="48.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Cmax in Plasma (Tmax) of M3 Metabolite</title>
        <description>Time to maximum plasma concentration of M3 Metabolite is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax in Plasma (Tmax) of M3 Metabolite</title>
          <description>Time to maximum plasma concentration of M3 Metabolite is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.01" lower_limit="12.00" upper_limit="36.00"/>
                    <measurement group_id="O2" value="24.02" lower_limit="4.00" upper_limit="36.00"/>
                    <measurement group_id="O3" value="16.00" lower_limit="5.00" upper_limit="36.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Cmax in Plasma (Tmax) of Esomeprazole</title>
        <description>Time to maximum plasma concentration of Esomeprazole is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax in Plasma (Tmax) of Esomeprazole</title>
          <description>Time to maximum plasma concentration of Esomeprazole is defined as first observed time to reach peak analyte concentration obtained directly from the experimental data without interpolation, expressed in time units and estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Last Quantifiable Concentration (Clast) of M2 Metabolite</title>
        <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Last Quantifiable Concentration (Clast) of M2 Metabolite</title>
          <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.515" spread="30.0"/>
                    <measurement group_id="O2" value="1.739" spread="29.4"/>
                    <measurement group_id="O3" value="1.682" spread="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Last Quantifiable Concentration (Clast) of M3 Metabolite</title>
        <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Last Quantifiable Concentration (Clast) of M3 Metabolite</title>
          <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.211" spread="46.2"/>
                    <measurement group_id="O2" value="2.279" spread="55.4"/>
                    <measurement group_id="O3" value="2.837" spread="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Last Quantifiable Concentration (Clast) of Esomeprazole</title>
        <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Last Quantifiable Concentration (Clast) of Esomeprazole</title>
          <description>Last quantifiable concentration is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.3" spread="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To the Last Quantifiable Concentration (Tlast) of M2 Metabolite</title>
        <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time To the Last Quantifiable Concentration (Tlast) of M2 Metabolite</title>
          <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.3" spread="21.2"/>
                    <measurement group_id="O2" value="142.4" spread="25.2"/>
                    <measurement group_id="O3" value="142.4" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To the Last Quantifiable Concentration (Tlast) of M3 Metabolite</title>
        <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time To the Last Quantifiable Concentration (Tlast) of M3 Metabolite</title>
          <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.0" spread="0.0"/>
                    <measurement group_id="O2" value="192.0" spread="0.0"/>
                    <measurement group_id="O3" value="168.7" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To the Last Quantifiable Concentration (Tlast) of Esomeprazole</title>
        <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time To the Last Quantifiable Concentration (Tlast) of Esomeprazole</title>
          <description>Time to last quantifiable concentration is based on last detectable concentration in the time curve.</description>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.002" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Phase Half-Life (T1/2) of M2 Metabolite</title>
        <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>For one participant in Balovaptan 20 mg Fasted and one participant in Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted AUC(0-inf)%extrap was &gt; 20%, so T1/2 were not included in summary statistics. For one additional participant in Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted there was no terminal phase, so AUC(0-inf) and T1/2 could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Phase Half-Life (T1/2) of M2 Metabolite</title>
          <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <population>For one participant in Balovaptan 20 mg Fasted and one participant in Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted AUC(0-inf)%extrap was &gt; 20%, so T1/2 were not included in summary statistics. For one additional participant in Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted there was no terminal phase, so AUC(0-inf) and T1/2 could not be calculated.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.99" spread="29.2"/>
                    <measurement group_id="O2" value="37.81" spread="30.7"/>
                    <measurement group_id="O3" value="39.19" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Phase Half-Life (T1/2) of M3 Metabolite</title>
        <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>For 3 subjects in Balovaptan 20 mg Fed, 3 subjects in Balovaptan 20 mg Fasted and 4 subjects in Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted AUC(0-inf)%extrap was &gt; 20%, so AUC(0-inf) were not included in summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Phase Half-Life (T1/2) of M3 Metabolite</title>
          <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <population>For 3 subjects in Balovaptan 20 mg Fed, 3 subjects in Balovaptan 20 mg Fasted and 4 subjects in Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted AUC(0-inf)%extrap was &gt; 20%, so AUC(0-inf) were not included in summary statistics.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.40" spread="17.3"/>
                    <measurement group_id="O2" value="59.30" spread="17.6"/>
                    <measurement group_id="O3" value="57.81" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Phase Half-Life (T1/2) of Esomeprazole</title>
        <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <population>For one participant AUC(0-inf)%extrap was &gt; 20%, so T1/2 was not included in summary statistics. For 2 participants, there was no terminal phase, so T1/2 could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Phase Half-Life (T1/2) of Esomeprazole</title>
          <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <population>For one participant AUC(0-inf)%extrap was &gt; 20%, so T1/2 was not included in summary statistics. For 2 participants, there was no terminal phase, so T1/2 could not be calculated.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.590" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patricipants With Adverse Events (AEs)</title>
        <time_frame>Randomization to end of study (up to approximately 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patricipants With Adverse Events (AEs)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Phase Rate Constant (Î»z) of Balovaptan</title>
        <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Rate Constant (Î»z) of Balovaptan</title>
          <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <units>/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0272" spread="33.3"/>
                    <measurement group_id="O2" value="0.0278" spread="37.5"/>
                    <measurement group_id="O3" value="0.0263" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Rate Constant (Î»z) of M2 Metabolite</title>
        <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>For one participant there was no terminal phase, so they are excluded form the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Rate Constant (Î»z) of M2 Metabolite</title>
          <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <population>For one participant there was no terminal phase, so they are excluded form the analysis.</population>
          <units>/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0178" spread="30.3"/>
                    <measurement group_id="O2" value="0.0174" spread="31.9"/>
                    <measurement group_id="O3" value="0.0171" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Rate Constant (Î»z) of M3 Metabolite</title>
        <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>For one participant there was no terminal phase, so they are excluded form the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Rate Constant (Î»z) of M3 Metabolite</title>
          <description>Terminal phase rate constant is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <population>For one participant there was no terminal phase, so they are excluded form the analysis.</population>
          <units>/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0112" spread="22.1"/>
                    <measurement group_id="O2" value="0.0107" spread="24.8"/>
                    <measurement group_id="O3" value="0.0107" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Rate Constant (Î»z) of Esomeprazole</title>
        <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <population>For two participants there was no terminal phase, so they are excluded form the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Rate Constant (Î»z) of Esomeprazole</title>
          <description>Terminal phase half-life expressed in time units is estimated using non-compartmental methods from the concentration-time profiles.</description>
          <population>For two participants there was no terminal phase, so they are excluded form the analysis.</population>
          <units>/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4197" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentrations of Balovaptan</title>
        <description>Amount of Balovaptan in a given volume of plasma.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>Number of analyzed participants reflects number of participants whose samples were available at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Balovaptan</title>
          <description>Amount of Balovaptan in a given volume of plasma.</description>
          <population>Number of analyzed participants reflects number of participants whose samples were available at given timepoint.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="246.8"/>
                    <measurement group_id="O2" value="2.46" spread="136.0"/>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.89" spread="235.7"/>
                    <measurement group_id="O2" value="21.26" spread="117.5"/>
                    <measurement group_id="O3" value="8.40" spread="129.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.76" spread="113.0"/>
                    <measurement group_id="O2" value="63.58" spread="60.9"/>
                    <measurement group_id="O3" value="44.78" spread="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.08" spread="88.2"/>
                    <measurement group_id="O2" value="66.54" spread="47.4"/>
                    <measurement group_id="O3" value="49.82" spread="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.47" spread="77.0"/>
                    <measurement group_id="O2" value="70.75" spread="32.9"/>
                    <measurement group_id="O3" value="62.24" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.90" spread="73.0"/>
                    <measurement group_id="O2" value="66.40" spread="33.4"/>
                    <measurement group_id="O3" value="63.44" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.92" spread="73.6"/>
                    <measurement group_id="O2" value="63.60" spread="29.7"/>
                    <measurement group_id="O3" value="66.26" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.68" spread="60.4"/>
                    <measurement group_id="O2" value="60.63" spread="31.2"/>
                    <measurement group_id="O3" value="64.70" spread="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.84" spread="50.2"/>
                    <measurement group_id="O2" value="59.58" spread="27.9"/>
                    <measurement group_id="O3" value="63.95" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.59" spread="36.5"/>
                    <measurement group_id="O2" value="59.56" spread="27.4"/>
                    <measurement group_id="O3" value="61.45" spread="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.91" spread="34.6"/>
                    <measurement group_id="O2" value="49.69" spread="28.3"/>
                    <measurement group_id="O3" value="54.51" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.07" spread="30.7"/>
                    <measurement group_id="O2" value="44.58" spread="30.0"/>
                    <measurement group_id="O3" value="48.05" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.18" spread="27.4"/>
                    <measurement group_id="O2" value="34.74" spread="32.9"/>
                    <measurement group_id="O3" value="35.91" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.17" spread="38.5"/>
                    <measurement group_id="O2" value="28.88" spread="37.5"/>
                    <measurement group_id="O3" value="30.85" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.43" spread="42.7"/>
                    <measurement group_id="O2" value="22.95" spread="43.6"/>
                    <measurement group_id="O3" value="25.95" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.94" spread="57.1"/>
                    <measurement group_id="O2" value="13.92" spread="55.4"/>
                    <measurement group_id="O3" value="15.13" spread="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" spread="70.5"/>
                    <measurement group_id="O2" value="10.70" spread="7.376"/>
                    <measurement group_id="O3" value="12.15" spread="6.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="90.2"/>
                    <measurement group_id="O2" value="4.28" spread="97.8"/>
                    <measurement group_id="O3" value="5.04" spread="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="112.0"/>
                    <measurement group_id="O2" value="2.86" spread="125.0"/>
                    <measurement group_id="O3" value="2.98" spread="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="186.5"/>
                    <measurement group_id="O2" value="2.45" spread="204.4"/>
                    <measurement group_id="O3" value="2.57" spread="198.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of M2 Analyte</title>
        <description>Amount of M2 Analyte in a given volume of plasma.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>Number of analyzed participants reflects number of participants whose samples were available at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of M2 Analyte</title>
          <description>Amount of M2 Analyte in a given volume of plasma.</description>
          <population>Number of analyzed participants reflects number of participants whose samples were available at given timepoint.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="3.081" spread="62.2"/>
                    <measurement group_id="O3" value="2.649" spread="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="3.421" spread="57.2"/>
                    <measurement group_id="O3" value="2.690" spread="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.021" spread="97.7"/>
                    <measurement group_id="O2" value="3.637" spread="45.6"/>
                    <measurement group_id="O3" value="3.019" spread="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.236" spread="83.3"/>
                    <measurement group_id="O2" value="3.724" spread="48.8"/>
                    <measurement group_id="O3" value="3.502" spread="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.714" spread="80.0"/>
                    <measurement group_id="O2" value="4.293" spread="49.9"/>
                    <measurement group_id="O3" value="3.878" spread="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.780" spread="75.7"/>
                    <measurement group_id="O2" value="4.724" spread="49.2"/>
                    <measurement group_id="O3" value="4.217" spread="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.208" spread="65.5"/>
                    <measurement group_id="O2" value="4.860" spread="49.1"/>
                    <measurement group_id="O3" value="4.749" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.756" spread="60.5"/>
                    <measurement group_id="O2" value="5.696" spread="47.9"/>
                    <measurement group_id="O3" value="5.471" spread="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.158" spread="50.9"/>
                    <measurement group_id="O2" value="5.797" spread="50.0"/>
                    <measurement group_id="O3" value="5.775" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.223" spread="48.9"/>
                    <measurement group_id="O2" value="6.550" spread="46.6"/>
                    <measurement group_id="O3" value="6.512" spread="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.921" spread="40.4"/>
                    <measurement group_id="O2" value="7.889" spread="39.5"/>
                    <measurement group_id="O3" value="8.426" spread="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.384" spread="39.7"/>
                    <measurement group_id="O2" value="9.207" spread="40.9"/>
                    <measurement group_id="O3" value="9.563" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.123" spread="29.4"/>
                    <measurement group_id="O2" value="10.928" spread="30.9"/>
                    <measurement group_id="O3" value="10.887" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.509" spread="29.6"/>
                    <measurement group_id="O2" value="10.519" spread="27.4"/>
                    <measurement group_id="O3" value="11.409" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.383" spread="28.2"/>
                    <measurement group_id="O2" value="9.134" spread="25.8"/>
                    <measurement group_id="O3" value="10.191" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.576" spread="30.7"/>
                    <measurement group_id="O2" value="5.998" spread="27.5"/>
                    <measurement group_id="O3" value="27.5" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.050" spread="41.6"/>
                    <measurement group_id="O2" value="3.748" spread="32.9"/>
                    <measurement group_id="O3" value="4.450" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.033" spread="64.7"/>
                    <measurement group_id="O2" value="2.139" spread="71.9"/>
                    <measurement group_id="O3" value="2.107" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of M3 Analyte</title>
        <description>Amount of M3 Analyte in a given volume of plasma.</description>
        <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
        <population>Number of analyzed participants reflects number of participants whose samples were available at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fed</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Balovaptan 20 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
          </group>
          <group group_id="O3">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of M3 Analyte</title>
          <description>Amount of M3 Analyte in a given volume of plasma.</description>
          <population>Number of analyzed participants reflects number of participants whose samples were available at given timepoint.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 1.00 ng/mL)</measurement>
                    <measurement group_id="O2" value="5.006" spread="118.0"/>
                    <measurement group_id="O3" value="3.172" spread="127.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.347" spread="138.4"/>
                    <measurement group_id="O2" value="7.812" spread="60.6"/>
                    <measurement group_id="O3" value="5.556" spread="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.787" spread="95.1"/>
                    <measurement group_id="O2" value="8.928" spread="59.6"/>
                    <measurement group_id="O3" value="6.705" spread="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.211" spread="83.0"/>
                    <measurement group_id="O2" value="10.157" spread="46.8"/>
                    <measurement group_id="O3" value="8.859" spread="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.520" spread="83.5"/>
                    <measurement group_id="O2" value="10.539" spread="47.9"/>
                    <measurement group_id="O3" value="9.853" spread="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.616" spread="85.9"/>
                    <measurement group_id="O2" value="10.980" spread="48.6"/>
                    <measurement group_id="O3" value="10.887" spread="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.985" spread="78.0"/>
                    <measurement group_id="O2" value="11.369" spread="50.8"/>
                    <measurement group_id="O3" value="11.316" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.408" spread="71.4"/>
                    <measurement group_id="O2" value="12.160" spread="50.8"/>
                    <measurement group_id="O3" value="11.969" spread="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.901" spread="58.8"/>
                    <measurement group_id="O2" value="13.241" spread="41.5"/>
                    <measurement group_id="O3" value="12.998" spread="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.691" spread="59.8"/>
                    <measurement group_id="O2" value="12.831" spread="47.9"/>
                    <measurement group_id="O3" value="13.442" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.157" spread="47.8"/>
                    <measurement group_id="O2" value="13.875" spread="48.4"/>
                    <measurement group_id="O3" value="13.762" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.697" spread="5.7063"/>
                    <measurement group_id="O2" value="14.296" spread="39.7"/>
                    <measurement group_id="O3" value="14.287" spread="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.113" spread="40.9"/>
                    <measurement group_id="O2" value="15.145" spread="41.6"/>
                    <measurement group_id="O3" value="15.049" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.388" spread="33.4"/>
                    <measurement group_id="O2" value="15.061" spread="39.7"/>
                    <measurement group_id="O3" value="16.092" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.626" spread="26.4"/>
                    <measurement group_id="O2" value="14.148" spread="29.7"/>
                    <measurement group_id="O3" value="13.793" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.665" spread="26.4"/>
                    <measurement group_id="O2" value="11.470" spread="29.0"/>
                    <measurement group_id="O3" value="12.966" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.108" spread="28.3"/>
                    <measurement group_id="O2" value="8.129" spread="31.3"/>
                    <measurement group_id="O3" value="9.023" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.066" spread="31.6"/>
                    <measurement group_id="O2" value="6.111" spread="42.4"/>
                    <measurement group_id="O3" value="6.653" spread="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.525" spread="45.5"/>
                    <measurement group_id="O2" value="3.747" spread="45.7"/>
                    <measurement group_id="O3" value="3.957" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 Hrs Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.211" spread="46.2"/>
                    <measurement group_id="O2" value="2.279" spread="55.4"/>
                    <measurement group_id="O3" value="2.569" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Esomeprazole</title>
        <description>Amount of Esomeprazole in a given volume of plasma.</description>
        <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
        <population>Number of analyzed participants reflects number of participants whose samples were available at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
            <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Esomeprazole</title>
          <description>Amount of Esomeprazole in a given volume of plasma.</description>
          <population>Number of analyzed participants reflects number of participants whose samples were available at given timepoint.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 2.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 2.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Below Quantifiable Limit (&lt; 2.00 ng/mL)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.8" spread="171.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.6" spread="102.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="697.1" spread="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="984.4" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="770.7" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.6" spread="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hrs Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.3" spread="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to end of study (up to approximately 7 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Balovaptan 20 mg Fed</title>
          <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were administered following consumption of a high-fat, high-calorie meal (Treatment A).</description>
        </group>
        <group group_id="E2">
          <title>Balovaptan 20 mg Fasted</title>
          <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were after a â¥ 10 h fast (Treatment B)</description>
        </group>
        <group group_id="E3">
          <title>Balovaptan 20 mg Fasted + Esomeprazole 40 mg Fasted</title>
          <description>Single oral doses of balovaptan 20 mg (1 Ã 20 mg tablet) were coadministered with esomeprazole 40 mg (Treatment C) in a fasted state.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

